Introduction
Standard cardiovascular risk assessment relies heavily on lipid panels — total cholesterol, LDL, HDL, and triglycerides. Yet half of all heart attacks occur in people with normal cholesterol levels. The missing piece is inflammation.
Inflammatory biomarkers — particularly high-sensitivity CRP, homocysteine, and fibrinogen — provide critical insight into the underlying inflammatory processes driving cardiovascular disease, often years before clinical events occur.
High-Sensitivity C-Reactive Protein (hsCRP)
What It Is
C-reactive protein (CRP) is an acute-phase protein produced by the liver in response to inflammatory cytokines, particularly IL-6. High-sensitivity CRP (hsCRP) measures very low levels of CRP that standard assays miss, making it a sensitive marker of chronic low-grade inflammation.
Cardiovascular Significance
The landmark JUPITER trial demonstrated that individuals with normal LDL but elevated hsCRP (above 2 mg/L) had significantly elevated cardiovascular risk — and benefited substantially from statin therapy. Subsequent research has confirmed hsCRP as an independent predictor of heart attack, stroke, and cardiovascular mortality.
Risk stratification by hsCRP:
- Low risk: below 1.0 mg/L
- Average risk: 1.0–3.0 mg/L
- High risk: above 3.0 mg/L (excluding acute infection or injury)
Root Cause Drivers of Elevated hsCRP
- Visceral adiposity — adipose tissue is a major source of IL-6 and TNF-α
- Gut dysbiosis and intestinal permeability — bacterial endotoxins (LPS) trigger hepatic CRP production
- Periodontal disease — chronic oral infection is a significant driver of systemic inflammation
- Insulin resistance and metabolic syndrome
- Sleep deprivation and circadian disruption
- Chronic psychological stress
- Dietary inflammatory load (excess omega-6, refined carbohydrates, ultra-processed foods)
Homocysteine
What It Is
Homocysteine is a sulfur-containing amino acid produced during the metabolism of methionine. It is normally remethylated back to methionine (requiring folate, B12, and the MTHFR enzyme) or transsulfurated to cysteine (requiring B6). When these pathways are impaired, homocysteine accumulates in the blood.
Cardiovascular Significance
Elevated homocysteine (above 10–12 μmol/L) is an independent risk factor for cardiovascular disease, stroke, and venous thromboembolism. Homocysteine directly damages the endothelium, promotes oxidative stress, impairs nitric oxide production, activates smooth muscle cell proliferation, and has prothrombotic effects.
Optimal homocysteine levels are generally considered below 7–8 μmol/L for cardiovascular protection.
Root Cause Drivers of Elevated Homocysteine
- B vitamin deficiencies — folate, B12, and B6 are the primary cofactors for homocysteine metabolism; deficiency is the most common cause of elevation
- MTHFR polymorphisms — C677T and A1298C variants reduce methylenetetrahydrofolate reductase activity, impairing folate-dependent remethylation
- Renal dysfunction — the kidneys play a key role in homocysteine clearance; impaired kidney function elevates levels
- Hypothyroidism — reduces the activity of enzymes involved in homocysteine metabolism
- Medications — metformin, methotrexate, proton pump inhibitors, and nitrous oxide deplete B12 and folate
- Excess methionine intake — high animal protein diets without adequate B vitamins can elevate homocysteine
Intervention
Supplementation with methylfolate (5-MTHF), methylcobalamin (B12), and pyridoxal-5-phosphate (B6) effectively lowers homocysteine in most cases. For MTHFR variants, active (methylated) forms of these vitamins are essential.
Fibrinogen
Fibrinogen is a clotting protein and acute-phase reactant that reflects both inflammatory burden and thrombotic risk. Elevated fibrinogen (above 350–400 mg/dL) is associated with increased risk of arterial thrombosis, stroke, and cardiovascular events. It is driven by the same inflammatory signals as CRP and is particularly elevated in smokers, diabetics, and those with metabolic syndrome.
Additional Cardiovascular Inflammation Markers
- Lipoprotein-associated phospholipase A2 (Lp-PLA2) — vascular-specific inflammatory enzyme; reflects active plaque inflammation rather than systemic inflammation
- Interleukin-6 (IL-6) — upstream driver of CRP production; reflects active inflammatory signaling
- Myeloperoxidase (MPO) — released by activated neutrophils and macrophages; directly oxidizes LDL and reflects plaque vulnerability
- Oxidized LDL (oxLDL) — direct marker of atherogenic LDL modification and oxidative stress
- GlycA — NMR-based composite inflammatory marker; may be more stable and predictive than hsCRP
Integrative Strategies to Reduce Cardiovascular Inflammation
- Omega-3 fatty acids (EPA/DHA) — 2–4 g/day; reduce IL-6, CRP, and fibrinogen
- Curcumin — potent NF-κB inhibitor; reduces hsCRP and multiple inflammatory cytokines
- Methylated B vitamins — 5-MTHF, methylcobalamin, P5P; lower homocysteine and support methylation
- Gut restoration — probiotics, prebiotics, and intestinal permeability support to reduce LPS-driven inflammation
- Anti-inflammatory diet — Mediterranean pattern reduces hsCRP by 20–30% in clinical trials
- Exercise — regular aerobic activity is one of the most effective anti-inflammatory interventions
- Periodontal care — treating gum disease significantly reduces systemic hsCRP
Conclusion
Cardiovascular inflammation markers — hsCRP, homocysteine, fibrinogen, and beyond — provide a window into the inflammatory processes driving vascular disease long before clinical events occur. Identifying and addressing the root causes of their elevation is a cornerstone of integrative cardiovascular prevention.
Explore the full Cardiovascular Health Hub for deeper dives into endothelial function, lipid optimization, and integrative cardiovascular protocols.
0 comments